CTA
MRNA icon

Carillon Tower Advisers’s Moderna MRNA Stock Holding History

Carillon Tower Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$57.5M Buy
+550,235
New +$55.7M 0.35% 92
2020
Q3 		– Sell
-550,235
Closed -$35.3M – 467
2020
Q2 		$35.3M Buy
+550,235
New +$30.1M 0.27% 118

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Carillon Tower Advisers's MRNA Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Moderna (MRNA) in Q4 2020: 550,235 shares worth $57.5M. The stake represents 0.35% of the portfolio and ranks #92 among its holdings. This is a return to the name: Carillon Tower Advisers previously reported a position in MRNA as recently as Q2 2020.

Carillon Tower Advisers first reported a position in MRNA in Q2 2020 and has held it in 2 quarters since. 718 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

  • Carillon Tower Advisers held 550,235 shares of Moderna worth $57.5M as of Q4 2020.
  • Moderna was a new Carillon Tower Advisers position in Q4 2020.
  • Moderna made up 0.35% of Carillon Tower Advisers's portfolio in Q4 2020, its #92 holding.
  • Carillon Tower Advisers first reported a position in Moderna in Q2 2020 and has held it in 2 quarters since.
  • 718 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.